Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 4
1997 9
1998 13
1999 9
2000 17
2001 17
2002 22
2003 22
2004 36
2005 29
2006 28
2007 26
2008 27
2009 23
2010 25
2011 23
2012 14
2013 11
2014 20
2015 16
2016 14
2017 17
2018 15
2019 11
2020 13
2021 22
2022 11
2023 14
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Results by year

Filters applied: . Clear all
Page 1
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3.5%) of 1325 patients in the …
Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in …
Atrasentan for the treatment of diabetic nephropathy.
Egido J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz AB, Gonzalez Parra E, Gomez-Guerrero C. Egido J, et al. Expert Opin Investig Drugs. 2017 Jun;26(6):741-750. doi: 10.1080/13543784.2017.1325872. Expert Opin Investig Drugs. 2017. PMID: 28468519 Review.
Both dual ETAR/ET(B)R (bosentan) or ET(A)R specific endothelin antagonists (avosentan and atrasentan, among others), which have progressed to early clinical development, with particular emphasis on atrasentan. ...Therefore, we eagerly but cautiously await the result …
Both dual ETAR/ET(B)R (bosentan) or ET(A)R specific endothelin antagonists (avosentan and atrasentan, among others), which have progr …
Atrasentan Abbott.
Norman P. Norman P. Curr Opin Investig Drugs. 2002 Aug;3(8):1240-8. Curr Opin Investig Drugs. 2002. PMID: 12211423 Review.
Atrasentan is a selective endothelin ET(A) receptor antagonist under development by Abbott for the potential treatment of cancer, particularly prostate cancer, for which it is in phase III trials [413197]. ...Atrasentan has also been in phase I trials for hypertensi …
Atrasentan is a selective endothelin ET(A) receptor antagonist under development by Abbott for the potential treatment of cancer, par …
Atrasentan: a rationally designed targeted therapy for cancer.
Jimeno A, Carducci M. Jimeno A, et al. Drugs Today (Barc). 2006 May;42(5):299-312. doi: 10.1358/dot.2006.42.5.973590. Drugs Today (Barc). 2006. PMID: 16801993 Review.
Endothelin axis deregulation triggers a series of events that ultimately activates proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively ta …
Endothelin axis deregulation triggers a series of events that ultimately activates proliferation, invasion, escape from programmed cell deat …
Atrasentan: targeting the endothelin axis in prostate cancer.
Jimeno A, Carducci M. Jimeno A, et al. Expert Opin Investig Drugs. 2004 Dec;13(12):1631-40. doi: 10.1517/13543784.13.12.1631. Expert Opin Investig Drugs. 2004. PMID: 15566319 Review.
Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cellular events such as proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and the alterat …
Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cel …
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Jimeno A, Carducci M. Jimeno A, et al. Expert Rev Anticancer Ther. 2005 Jun;5(3):419-27. doi: 10.1586/14737140.5.3.419. Expert Rev Anticancer Ther. 2005. PMID: 16001950 Review.
Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively tar …
Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death …
Novel Therapies for Alport Syndrome.
Chavez E, Rodriguez J, Drexler Y, Fornoni A. Chavez E, et al. Front Med (Lausanne). 2022 Apr 25;9:848389. doi: 10.3389/fmed.2022.848389. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35547199 Free PMC article. Review.
Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type A receptor (ETAR) and angiotensin 1 receptor inhibitor; atrasentan, oral selective ETAR inhibitor; lipid-modifying agents, including …
Our review will include bardoxolone methyl, an oral NRf2 activator; lademirsen, an anti-miRNA-21 molecule; sparsentan, dual endothelin type …
Endothelin Receptor Antagonists in Kidney Disease.
Martínez-Díaz I, Martos N, Llorens-Cebrià C, Álvarez FJ, Bedard PW, Vergara A, Jacobs-Cachá C, Soler MJ. Martínez-Díaz I, et al. Int J Mol Sci. 2023 Feb 8;24(4):3427. doi: 10.3390/ijms24043427. Int J Mol Sci. 2023. PMID: 36834836 Free PMC article. Review.
Currently, the efficacy of many ERAs to treat kidney disease is being tested in randomized controlled trials; however, some of these, such as avosentan and atrasentan, were not commercialized due to the adverse events related to their use. ...
Currently, the efficacy of many ERAs to treat kidney disease is being tested in randomized controlled trials; however, some of these, such a …
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Smeijer JD, Kohan DE, Rossing P, Correa-Rotter R, Liew A, Tang SCW, de Zeeuw D, Gansevoort RT, Ju W, Lambers Heerspink HJ. Smeijer JD, et al. Cardiovasc Diabetol. 2023 Sep 16;22(1):251. doi: 10.1186/s12933-023-01964-8. Cardiovasc Diabetol. 2023. PMID: 37716952 Free PMC article.
In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9). ...SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532....
In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9). ...SONAR trial ( …
471 results